Results 141 to 150 of about 255,779 (244)

Oncolytic Probiotics with Molecular Pili for Solid Tumor Therapy

Advanced Science, EarlyView.
This study identifies Lactobacillus rhamnosus as an intrinsic oncolytic agent that triggers tumor metabolic collapse via calcium‐dependent ROS bursts. By chemically anchoring collagen‐targeting “molecular pili” to the bacterial surface, the engineered non‐transgenic probiotic (LR@MP) achieves targeted colonization and potent solid tumor suppression ...
Haodong Ge, Chengsheng Ding, Xiao Yang, Si Gao, Changjie Yang, Yuchen Hou, Hongye Wang, Linke Bian, Hao Zhong, Yifan Qu, Luyang Zhang, Junjun Ma, Zhengwei Cai, Wenguo Cui, Minhua Zheng   +14 more
wiley   +1 more source

High‐Content SRS Imaging Unveils Altered Cholesterol Metabolism in Ovarian Cancers Under CAR‐T Treatment

Advanced Science, EarlyView.
High‐content Stimulated Raman Scattering (SRS) Imaging reveals that ovarian cancer cells surviving Chimeric Antigen Receptor (CAR) ‐T cell challenge exhibit increased cholesterol esterification. Pharmacological inhibition of this pathway with Avasimibe significantly enhances CAR‐T induced killing of ovarian cancer cells by reducing cancer cell ...
Chinmayee V. Prabhu Dessai, Zhuoying Huang, Haonan Lin, Guangrui Ding, Hongjian He, Menna Siddiqui, Meng Zhang, Wilson Wong, Ji‐Xin Cheng   +8 more
wiley   +1 more source

Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation

Nature Communications
Immune checkpoint inhibition targeting the PD-1/PD-L1 pathway has become a powerful clinical strategy for treating cancer, but its efficacy is complicated by various resistance mechanisms.
Xiaoyan Xu, Tingxue Xie, Mengxin Zhou, Yaqin Sun, Fengqi Wang, Yanan Tian, Ziyan Chen, Yanqi Xie, Ronghai Wu, Xufeng Cen, Jichun Zhou, Tingjun Hou, Lei Zhang, Chaoyang Huang, Qingwei Zhao, Dongrui Wang, Hongguang Xia   +16 more
doaj   +1 more source

Universal Antibody‐Engineered Lipid Nanoparticles Potentiate Chemo‐Immunotherapy Against Triple‐Negative Breast Cancer by Reprogramming Tumor Cell Metabolism

Advanced Science, EarlyView.
A universal ROR1 antibody‐engineered lipid nanoparticle (LNP) is constructed by sequential drug encapsulation and antibody conjugation. The LNP not only enables enhanced chemotherapeutic efficiency by targeting drug delivery and precise localization of deep‐seated tumors through NIR‐II fluorescence imaging, but also remodels immunosuppressive TME ...
Yeneng Dai, Jiaqi Wang, Yu Liu, Guanda Jiao, Yuheng Gu, Yang Liu, Shengyu Fu, Xing Fan, Jialin Li, Ziang Guo, Kam Tong Leung, Lipeng Zhu, Qi Zhao   +12 more
wiley   +1 more source

Context‐Dependent Role of GDF15: GDF15+ Tumor‐Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis

Advanced Science, EarlyView.
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou, Zhihang Zhou, Houyu Ju, Chaoyang Guo, Fangxing Zhu, Yiyi Zhang, Xu Chen, Tongchao Zhao, Laiping Zhong, Jingzhou Hu   +9 more
wiley   +1 more source

Potent and Selective IGF‐IIR‐Recruiting Bifunctional Molecules for Targeted Lysosomal Degradation of Extracellular and Membrane Proteins

Advanced Science, EarlyView.
Lysosome‐targeting chimeras (LYTACs) enable degradation of extracellular and membrane proteins via lysosomal trafficking. We report a novel IGF‐II mutant (Del1–7, Y27L) that selectively engages IGF‐IIR while avoiding IGF‐IR and IR‐A. mutIGF‐II–based LYTACs enhance target internalization and degradation and support a genetically encodable, all‐protein ...
Yuan Zhao, Yaxian Liao, Pengyun Li, Regina Stasser de Gonzalez, Xuankun Chen, Nicholas S. Nieto, Florence M. Brunel, Nick Cox, Joseph Stock, Matthew McHenry, Guangsen Fu, Penghsuan Huang, Wenxin Wu, Deqin Cai, Lingjun Li, Alexander N. Zaykov, Weiping Tang   +16 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2− Breast Cancer

Advanced Science, EarlyView.
Multi‐omics and single‐cell analyses identify activated NK cells as key mediators of anti‐PD‐(L)1 response in HR+/HER2− breast cancer. Platinum chemotherapy enhances NK cell cytotoxicity through NF‐κB–associated signaling, synergizing with immunotherapy and providing a rationale for combination treatment.
Yi‐Yu Chen, Yi‐Fan Zhou, Xuan Qi, Ya‐Xin Zhao, Tong Fu, Xi Jin, Minhong Shen, Yi‐Zhou Jiang, Zhi‐Ming Shao   +8 more
wiley   +1 more source

Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy‐Induced Cardiac Fibrosis Based on Single‐Cell Transcriptomic Analysis

Advanced Science, EarlyView.
This study highlights that radioimmunotherapy drives crosstalk between fibroblasts and immune cells (especially macrophages) in the cardiac microenvironment, with IL‐6 as the key mediator, and tocilizumab alleviates cardiac fibrosis by targeting this interplay.
Yuxi Luo, Ying Yu, Zhimin Zeng, Yanxin Chen, Yali Yi, Zhiqin Lu, Fujuan Zeng, Peng Xu, Daya Luo, Leifeng Chen, Anwen Liu   +10 more
wiley   +1 more source

PD-L1 status on circulating tumor cells: a promising predictor in advanced lung cancer with PD-1/PD-L1 immunotherapies. [PDF]

Eur J Med Res
Wei X, Chen L, Yang Z, Zeng D, Tang D, Jiang J.   +5 more
europepmc   +1 more source